Quotient Clinical Expands Data Sciences Capability
News Sep 28, 2016
Quotient Clinical has announced the expansion of its Data Sciences function with relocation to a larger office, staying in Edinburgh. The expansion comes in response to growing customer demand for the Data Sciences service. The total Data Sciences headcount has increased by more than 34% during the past two years and is now at over 50 employees. Quotient Clinical is currently actively recruiting. Quotient Clinical’s Data Sciences offering supports its proprietary Translational Pharmaceutics platform, which integrates formulation development, real-time adaptive GMP manufacturing and clinical testing.
The Data Sciences experts provide bespoke services for early phase clinical studies including: data management, eCRF programming, statistics and statistical programming, pharmacokinetic modelling and simulation, and medical writing. These capabilities deliver real-time data to customers for review and interpretation, enabling crucial dosing decisions to be made during the course of a study and to aid development of clinical programs post study.
Greg Johnson, VP Data Sciences, Quotient Clinical, commented: “Our unique Translational Pharmaceutics platform is increasingly being recognised in the industry for reducing clinical development timelines, cutting associated costs, and offering enhanced data-based decision making ability throughout the process. As a consequence, demand for our integrated Data Sciences service is also growing, and we are therefore delighted to announce this expansion and the move to a new larger office, ensuring that customers continue to receive the highest standard of service.”
Translational Pharmaceutics brings innovation to early drug development by integrating formulation development, real-time adaptive GMP manufacturing and clinical testing within a single organisation. Drug products are manufactured in real-time immediately prior to clinical testing, creating the opportunity to modify dose and formulation compositions in response to emerging clinical data (safety, pharmacokinetic or pharmacodynamic). The platform can be applied to a wide range of drug products, including oral, inhaled, dermal and IV, and encompasses simple and complex formulation types.
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE
A new study by investigators from Brigham and Women’s Hospital examined whether pregnancy-related changes may influence how effectively five common AEDs prevent seizures and found that antiepileptic drug clearance significantly changes by the first trimester for the most commonly used medication and by the second trimester for two others.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019